Posts Tagged ‘Glaucoma’
Lindstrom Eyes Improvements to Eye Drops
Richard Lindstrom, MD, led the OIS@ASRCS breakfast breakout session “Innovative Alternatives to Drops.” Hear his recap of the problem and the potential solutions that may someday help current and new medicines reach the areas of the eye that need them most. Video Highlights: 00:48 – If everyone used their eye drops they’d be quite safe…
Read MoreWhat the Heck Happened at OIS@ASCRS? – OIS Podcasts Hit Some Highlights from Last Week’s Stellar Meeting in New Orleans
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 085″] The fifth OIS@ASCRS delivered highlights on diagnostics, glaucoma devices, and What The Future of ophthalmology might bring. OIS Podcasts will provide a quick review of the day for those who couldn’t make it (or simply had overstuffed their meeting calendar in New Orleans). Tom Salemi: Hi, Everyone, welcome back to…
Read MoreMixing MIGS & Meds
Long gone are the days where glaucoma surgery meant an invasive procedure with the likelihood of a serious complication developing down the road – while trabeculectomy is still a viable option, its side-effect profile is relegating it to more of a final option. These days, surgeons are much more likely to recommend minimally invasive glaucoma…
Read MoreSun Ophthalmics Looks to Build a Brand-New Business in the US
Sun Pharma, the fifth largest pharma company in the US, targeted ophthalmology as one of the first planks in its new branded pharma business. Hear ophthalmology veteran Jerry St. Peter explain how Sun Ophthalmics hopes to build a new team in ophthalmology. Ten Top Topics in this OIS Podcast: What are the origins of Sun…
Read MoreIridex Makes its Move in Glaucoma
Over the past couple of years, there has been no shortage of positive news about the glaucoma space. While minimally invasive glaucoma surgery (MIGS) has totally captured the limelight, Iridex Corp. has quietly begun to build momentum with its Cyclo G6 laser. Iridex has a more than 30-year track record in laser photocoagulation and a…
Read MoreWithout Pfizer Deal, Allergan Looks Ahead: Could B+L be in its Sights?
Now that Pfizer and Allergan have mutually agreed to terminate their proposed merger, Allergan CEO Brent Saunders told analysts Wednesday morning that the company is moving ahead with new product development, but he would not rule out the possibility of Allergan making a play for his old employer, Bausch + Lomb. The merger foundered when…
Read MoreEye on Five – March Edition
Regeneron, Bayer Join to Develop Combined Therapy Regeneron Pharmaceuticals and Bayer announced an agreement to jointly develop a combination therapy of the angiopoietin2 (Ang2) antibody nesvacumab and aflibercept for the treatment of wet age-related macular degeneration or diabetic macular edema. Two separate Phase II clinical studies are evaluating the combination therapy as a co-formulated, single…
Read MoreMixed Results Don’t Sidetrack Rhopressa Plans
Despite tepid investor response to safety data from the latest comparative trial of its lead-candidate glaucoma agent, Aerie Pharmaceuticals says it is still on track to file a New Drug Application for the agent in the third quarter of this year. However, investors focusing on that data, from the Rocket 1 and 2 trials, may…
Read MoreLewis Handicaps MIGS Market & Explains Glaucoma’s Emergence
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 077″] Glaucoma specialist Dr. Richard Lewis says glaucoma was once the “boring step sister” of the ophthalmology world. But now the chief medical officer of Aerie says the rise in devices and drugs has made glaucoma one of the coolest kids in ophthalmology’s school yard. 10 Top Topics in this OIS…
Read MoreHighlights from AGS: New Surgical Devices, Novel Therapeutics
This year’s American Glaucoma Society annual meeting feted novel medications designed to lower intraocular pressure (IOP) in patients with glaucoma. To date, available medications and surgery are designed to treat one of the primary risk factors – elevated IOP. But they are not designed to directly target the underlying degeneration that’s causing the vision loss.…
Read MoreEye on Five – February Edition 2016
The Transcend acquisition tops the list, but February was a promising month for ophthalmology. Alcon Leaps into MIGS with Transcend With its acquisition of Transcend Medical and its CyPass Micro-Stent platform for glaucoma, Novartis aims to kick start the lackluster growth of its Alcon unit by tapping into the high-growth micro-invasive glaucoma surgery device market…
Read MoreKOL Corner: Alcon, Transcend & Glaucoma 360
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 074″] Glaucoma once might have been a boring or sleepy sub-specialty of ophthalmology, but recent technical advances and significant bets placed by large strategics including Alcon’s planned ac-quisition of Transcend has injected the sector with enthusiasm and energy. OIS Podcast, in our new KOL Corner features, talks with leading glaucoma specialists…
Read More